Dr. Jens Reinhardt is assessor for quality and non-clinic in the Division of Medical Biotechnology at the Paul-Ehrlich-Institut.
Before joining the PEI in 2008, he worked as postdoctoral fellow at the Stanford University, at the Station Biologique de Roscoff (France), and at a biotech company in Munich.
At the PEI he is assessing clinical trial applications and marketing authorisation applications for advanced therapy medicinal products. He is part of the team that provides national scientific advice at PEI. He was also involved in the assessment of marketing authorisation applications for vaccines against pandemic influenza. Since 2011 Dr Reinhardt is Alternate Member of the Scientific Advice Working Party at the European Medicines Agency in London.